Active substance
Rifapentine
- US FDA 2
- US price lines 1
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PRIFTIN | 150MG | tablet · oral | SANOFI AVENTIS US | Prescription | 22 Jun 1998 |
| RIFAPENTINE | 150MG | tablet · oral | MACLEODS PHARMS | Prescription | 23 Jun 2026 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PRIFTIN 150 MG TABLET | $4.82801 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.5. Antituberculosis medicines · core
Latent tuberculosis; Tuberculosis
Oral > Solid > dispersible tablet: 150 mg (EMLc) | Oral > Solid > tablet: 150 mg; 300 mg
Safety signals and safety-related labeling changes
- US FDA 27 Jan 2026 PRIFTIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.